Repository logo
Log in(current)
Repository logoMIT Open ScholarshipDSpace@MIT
  1. Home
  2. MIT Open Access Articles
  3. MIT Open Access Articles
  4. Camptothecin resistance is determined by the regulation of topoisomerase I degradation mediated by ubiquitin proteasome pathway

Camptothecin resistance is determined by the regulation of topoisomerase I degradation mediated by ubiquitin proteasome pathway

Thumbnail Image
Download
Name

Ando-2017-Camptothecin resistance is determine.pdf

Size

2.23 MB

Format

Adobe PDF

Checksum (MD5)

98ab2e9e47839c429cd416c0aaaf89db

Author(s)
Ando, Koji
•
Shah, Ankur K.
•
Sachdev, Vibhu
•
Kleinstiver, Benjamin P.
•
Taylor-Parker, Julian
•
Welch, Moira M.
•
Hu, Yiheng
•
Salgia, Ravi
•
Parvin, Jeffrey D.
•
Ozonoff, Al
more
Date Issued
March 2017
Journal
Oncotarget
Publisher
Impact Journals/National Center for Biotechnology Information (U.S.)
Citation
Ando, Koji; Shah, Ankur K.; Sachdev, Vibhu; Kleinstiver, Benjamin P.; Taylor-Parker, Julian; Welch, Moira M.; Hu, Yiheng et al. “Camptothecin Resistance Is Determined by the Regulation of Topoisomerase I Degradation Mediated by Ubiquitin Proteasome Pathway.” Oncotarget (November 2015): 16376
Version
Final published version
Abstract
Proteasomal degradation of topoisomerase I (topoI) is one of the most remarkable cellular phenomena observed in response to camptothecin (CPT). Importantly, the rate of topoI degradation is linked to CPT resistance. Formation of the topoI-DNA-CPT cleavable complex inhibits DNA re-ligation resulting in DNA-double strand break (DSB). The degradation of topoI marks the first step in the ubiquitin proteasome pathway (UPP) dependent DNA damage response (DDR). Here, we show that the Ku70/Ku80 heterodimer binds with topoI, and that the DNA-dependent protein kinase (DNA-PKcs) phosphorylates topoI on serine 10 (topoI-pS10), which is subsequently ubiquitinated by BRCA1. A higher basal level of topoI-pS10 ensures rapid topoI degradation leading to CPT resistance. Importantly, PTEN regulates DNA-PKcs kinase activity in this pathway and PTEN deletion ensures DNA-PKcs dependent higher topoI-pS10, rapid topoI degradation and CPT resistance.
MIT Department
Massachusetts Institute of Technology. Department of Biological Engineering
Koch Institute for Integrative Cancer Research at MIT
Terms of Use
Creative Commons Attribution 3.0 Unported license
http://creativecommons.org/licenses/by/3.0/
Persistent DSpace Link
http://hdl.handle.net/1721.1/109949
DOI of Published Version
https://doi.org/10.18632/oncotarget.16376
Repository logo
PrivacyPermissionsAccessibilityContact us
Repository logo
Notify us about copyright concerns.